Loading
companiesCompany
Eikon Therapeutics
Eikon Therapeutics is a United States-based biotechnology company running 6 late-stage cancer trials of EIK1001, EIK1004-001 (IMP1707-001) and IMP1734 in melanoma, non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer.
Overview
Eikon Therapeutics, based in Millbrae, California, the United States, is a biotechnology company. A drug discovery company that also has offices in New York and Jersey City and lists clinical-stage oncology, immunology and neuroscience programmes on its pipeline page, including TLR7/8, PARP1, PARP1-CNS penetrant, AR, VCP and AR-v7 targeted programmes. On ClinicalTrials.gov it is the lead sponsor of 6 recruiting or active phase 2 and phase 3 interventional cancer trials (2 in phase 3), testing EIK1001, EIK1004-001 (IMP1707-001), IMP1734 and EIK1005 in melanoma, non-small-cell lung cancer, gastric & gastro-oesophageal junction cancer, colorectal cancer and endometrial cancer. The largest, NCT07365319 (A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer), plans to enrol 750 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Headquarters
Millbrae, California, US
Scorecard
All companies#312of 1244 companies, score 13
- phase 3 +3
- phase 1/2 +2
- targets +2
- modalities +2
- registry trials +4
0 approved, 1 in phase 3, 2 earlier, 1 targets, 5 registry studies. Formula on the scorecards page.
Type
Website
Phase 3small molecule (structure undisclosed or not yet in PubChem)
EIK1001 is an experimental investigational agent whose form is not stated in the registry from Eikon Therapeutics in phase 3 trials for melanoma and non-small-cell lung cancer, with its target not yet stated publicly.
Phase 2Small-molecule inhibitor
EIK1005 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for colorectal cancer, endometrial cancer.
Phase 2Small-molecule inhibitor
IMP1734 is a small-molecule inhibitor from Eikon Therapeutics, in registered phase 2 trials for metastatic cancer.
Similar pages
- CompanyIMPACT Therapeutics
Shares A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors., A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors.
- TargetWRN helicase (MSI-high cancers)
Shares EIK1005, Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer.
cancers
drugs
companies
trials
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsA Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLCA Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung CancerA Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in ParticSafety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma